MiNK Therapeutics (INKT) Misses Q2 EPS by 106c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts INKT Hot Sheet
Join SI Premium – FREE
MiNK Therapeutics (NASDAQ: INKT) reported Q2 EPS of ($1.06).
For earnings history and earnings-related data on MiNK Therapeutics (INKT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kotak Upgrades Indusind Bank Ltd (IIB:IN) to Reduce (3)
- IndeRes Upgrades Nokia OYJ (NOKIA:FH) (NOK) to Reduce (3)
- ORIC Pharmaceuticals (ORIC) PT Raised to $18 at Stifel
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
